BACKGROUND: Myc-positive B-cell non-Hodgkin lymphoma (NHL) with or without a B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) rearrangement is associated with inferior progression-free survival (PFS) and overall survival (OS). In this study, the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University. METHODS: All patients who had non-Burkitt, aggressive B-cell NHL from 2008 to 2011 were assessed for the t(14;18) translocation and for v-myc avian myelocytomatosis viral oncogene homolog (CMYC) rearrangements at diagnosis, and all myc-positive patients were included in the current analysis. Associations with clinical characteristics were described, and univariable and multivariable models were used to assess correlations between clinical variables and outcomes. RESULTS: Of 49 myc-positive patients, 29 patients also had BCL2 rearrangements (double-hit NHL). No patients underwent autologous stem cell transplantation in first remission. For all myc-positive patients, the median PFS was 16.6 months, and the median OS was 37.7 months. For patients who had double-hit NHL, the median PFS was 8 months, and the median OS was 12.5 months; whereas the median PFS and OS were not reached for myc-positive patients. A complete response (CR) after front-line therapy, the presence of t(14;18), International Prognostic Index (IPI) group, and age were associated with PFS; whereas only the achievement of a CR and age >60 years were associated with OS in the multivariable setting. The median PFS was 3.3 months, and the median and OS was 7.0 months for patients who did not attain a CR; and the medians were not reached for patients who achieved a CR (P < .00001). CONCLUSIONS: The achievement of a CR with front-line therapy is associated with a prolonged PFS and OS in patients with myc-positive NHL, even after adjusting for type of initial therapy, histology, age, IPI, or the presence of a concurrent BCL2 translocation.
BACKGROUND:Myc-positive B-cell non-Hodgkin lymphoma (NHL) with or without a B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) rearrangement is associated with inferior progression-free survival (PFS) and overall survival (OS). In this study, the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University. METHODS: All patients who had non-Burkitt, aggressive B-cell NHL from 2008 to 2011 were assessed for the t(14;18) translocation and for v-myc avian myelocytomatosis viral oncogene homolog (CMYC) rearrangements at diagnosis, and all myc-positive patients were included in the current analysis. Associations with clinical characteristics were described, and univariable and multivariable models were used to assess correlations between clinical variables and outcomes. RESULTS: Of 49 myc-positive patients, 29 patients also had BCL2 rearrangements (double-hit NHL). No patients underwent autologous stem cell transplantation in first remission. For all myc-positive patients, the median PFS was 16.6 months, and the median OS was 37.7 months. For patients who had double-hit NHL, the median PFS was 8 months, and the median OS was 12.5 months; whereas the median PFS and OS were not reached for myc-positive patients. A complete response (CR) after front-line therapy, the presence of t(14;18), International Prognostic Index (IPI) group, and age were associated with PFS; whereas only the achievement of a CR and age >60 years were associated with OS in the multivariable setting. The median PFS was 3.3 months, and the median and OS was 7.0 months for patients who did not attain a CR; and the medians were not reached for patients who achieved a CR (P < .00001). CONCLUSIONS: The achievement of a CR with front-line therapy is associated with a prolonged PFS and OS in patients with myc-positive NHL, even after adjusting for type of initial therapy, histology, age, IPI, or the presence of a concurrent BCL2 translocation.
Authors: Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani Journal: Am J Surg Pathol Date: 2010-03 Impact factor: 6.394
Authors: Pei Lin; Timothy J Dickason; Luis E Fayad; Patrick A Lennon; Peter Hu; Mar Garcia; Mark J Routbort; Roberto Miranda; Xumei Wang; Wei Qiao; L Jeffrey Medeiros Journal: Cancer Date: 2011-08-31 Impact factor: 6.860
Authors: Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Amanda F Cashen; Farrokh Dehdashti; Jingqin Luo; Andrew Homb; Barry A Siegel; Nancy L Bartlett Journal: J Nucl Med Date: 2011-02-14 Impact factor: 10.057
Authors: Sharon Barrans; Simon Crouch; Alex Smith; Kathryn Turner; Roger Owen; Russell Patmore; Eve Roman; Andrew Jack Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Nathalie A Johnson; Kerry J Savage; Olga Ludkovski; Susana Ben-Neriah; Ryan Woods; Christian Steidl; Martin J S Dyer; Reiner Siebert; John Kuruvilla; Richard Klasa; Joseph M Connors; Randy D Gascoyne; Douglas E Horsman Journal: Blood Date: 2009-07-13 Impact factor: 22.113
Authors: Kerry J Savage; Nathalie A Johnson; Susana Ben-Neriah; Joseph M Connors; Laurie H Sehn; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne Journal: Blood Date: 2009-08-24 Impact factor: 22.113
Authors: Alex F Herrera; Matthew Mei; Lawrence Low; Haesook T Kim; Gabriel K Griffin; Joo Y Song; Reid W Merryman; Victoria Bedell; Christine Pak; Heather Sun; Tanya Paris; Tracey Stiller; Jennifer R Brown; Lihua E Budde; Wing C Chan; Robert Chen; Matthew S Davids; Arnold S Freedman; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Joyce Murata-Collins; Auayporn P Nademanee; Joycelynne M Palmer; German A Pihan; Raju Pillai; Leslie Popplewell; Tanya Siddiqi; Aliyah R Sohani; Jasmine Zain; Steven T Rosen; Larry W Kwak; David M Weinstock; Stephen J Forman; Dennis D Weisenburger; Young Kim; Scott J Rodig; Amrita Krishnan; Philippe Armand Journal: J Clin Oncol Date: 2016-10-24 Impact factor: 44.544
Authors: Alex F Herrera; Scott J Rodig; Joo Y Song; Young Kim; Gabriel K Griffin; Dongyun Yang; Liana Nikolaenko; Matthew Mei; Victoria Bedell; Paola Dal Cin; Christine Pak; Edwin P Alyea; Lihua E Budde; Robert Chen; Yi-Bin Chen; Wing C Chan; Corey S Cutler; Vincent T Ho; John Koreth; Amrita Krishnan; Joyce L Murata-Collins; Sarah Nikiforow; Joycelynne Palmer; German A Pihan; Raju Pillai; Leslie Popplewell; Steven T Rosen; Tanya Siddiqi; Aliyah R Sohani; Jasmine Zain; Larry W Kwak; Dennis D Weisenburger; David M Weinstock; Robert J Soiffer; Joseph H Antin; Stephen J Forman; Auayporn P Nademanee; Philippe Armand Journal: Biol Blood Marrow Transplant Date: 2017-11-28 Impact factor: 5.742
Authors: Soham D Puvvada; Patrick J Stiff; Michael Leblanc; James R Cook; Stephen Couban; John P Leonard; Brad Kahl; Deborah Marcellus; Thomas C Shea; Jane N Winter; Hongli Li; Lisa M Rimsza; Jonathan W Friedberg; Sonali M Smith Journal: Br J Haematol Date: 2016-04-13 Impact factor: 6.998
Authors: Shaoying Li; Annapurna Saksena; Parth Desai; Jie Xu; Zhuang Zuo; Pei Lin; Guilin Tang; C Cameron Yin; Adam Seegmiller; Jeffrey L Jorgensen; Roberto N Miranda; Nishitha M Reddy; Carlos Bueso-Ramos; L Jeffrey Medeiros Journal: Oncotarget Date: 2016-06-21